BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK), where he launched and commercialized Keytruda...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology at the Genentech Inc. unit of...
BioCentury | Nov 19, 2020
Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018. The group supplied €37 million ($43.9...
BioCentury | Jun 10, 2020
Finance

Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects

Four years after its launch as the manager of companies in J&J’s Belgian incubator, Bioqube Ventures has raised €60 million toward its first independent venture fund earmarked for European start-ups operating in its sweet spots...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jul 17, 2019
Preclinical News

July 17 Preclinical Quick Takes: Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

CRISPR can modify TCRs to reprogram T cells A Technical University Munich and Juno Therapeutics Inc. team led by TUM professor Dirk Busch used CRISPR to modify T cell receptors and create engineered T cells....
BioCentury | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
BioCentury | Apr 3, 2019
Finance

The dynamics of Dyne

Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1)....
BioCentury | Mar 6, 2019
Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

UCB Ventures hired Alicia Irurzun-Lafitte as a partner. She was a principal at M Ventures, the corporate venture fund of Merck KGaA (Xetra:MRK). GlycoMimetics Inc. (NASDAQ:GLYC) said Chairman Jim Barrett will retire from the board....
Items per page:
1 - 10 of 98
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 2, 2021
Management Tracks

Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem

Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK), where he launched and commercialized Keytruda...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology at the Genentech Inc. unit of...
BioCentury | Nov 19, 2020
Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018. The group supplied €37 million ($43.9...
BioCentury | Jun 10, 2020
Finance

Belgium’s Bioqube earmarking some of planned €100M fund for ‘de-risking’ projects

Four years after its launch as the manager of companies in J&J’s Belgian incubator, Bioqube Ventures has raised €60 million toward its first independent venture fund earmarked for European start-ups operating in its sweet spots...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jul 17, 2019
Preclinical News

July 17 Preclinical Quick Takes: Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

CRISPR can modify TCRs to reprogram T cells A Technical University Munich and Juno Therapeutics Inc. team led by TUM professor Dirk Busch used CRISPR to modify T cell receptors and create engineered T cells....
BioCentury | Jul 8, 2019
Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
BioCentury | Apr 3, 2019
Finance

The dynamics of Dyne

Incubated by Atlas Venture and launched Wednesday with a $50 million series A round, Dyne Therapeutics Inc. is using its muscle-targeting platform to develop therapies for rare diseases, beginning with myotonic dystrophy type 1 (DM1)....
BioCentury | Mar 6, 2019
Company News

Management tracks: UCB Ventures, GlycoMimetics, Fluidigm

UCB Ventures hired Alicia Irurzun-Lafitte as a partner. She was a principal at M Ventures, the corporate venture fund of Merck KGaA (Xetra:MRK). GlycoMimetics Inc. (NASDAQ:GLYC) said Chairman Jim Barrett will retire from the board....
Items per page:
1 - 10 of 98